Diseases Caused by Streptococcus Pneumoniae Serotypes

Infectious Diseases
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Walvax Biotechnology
Walvax BiotechnologyChina - Kunming
1 program
1
7-valent pneumococcal conjugate vaccinePhase 3Vaccine1 trial
Active Trials
NCT02736240CompletedEst. Dec 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Walvax Biotechnology7-valent pneumococcal conjugate vaccine

Clinical Trials (1)

NCT02736240Walvax Biotechnology7-valent pneumococcal conjugate vaccine

Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)

Start: Apr 2016Est. completion: Dec 2017
Phase 3Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space